Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
With Heidi Overton out, who’s gonna lead the FDA? We should endeavor a guess, March Madness-style. STAT Madness, regulatory edition.
Merck enlists Isomorphic for mystery target
Merck already has an oncology target it considers strategically important — and a trove of wet lab data from its own work on it. Now, STAT’s Katherine MacPhail writes exclusively, it’s bringing in Isomorphic Labs to see whether the DeepMind spinoff’s AI models can use those data to find promising small molecules faster.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
